AMSTERDAM, the Netherlands, May 12, 2016 -- uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced that its management will be presenting at the below listed investor conferences in May and June, 2016.
- Piper Jaffray GenomeRx Symposium
Venue: The InterContinental New York Barclay Hotel, New York City
Title: Getting to the Heart (& Muscle) of the Gene Therapy Matter
Presenter: Christian Meyer, Chief Medical Officer
Date and Time: May 17, 2016: 10.40 AM EDT
- 2016 UBS Global Healthcare Conference
Venue: Grand Hyatt New York Hotel, New York City
Presenter: Daniel Soland, Chief Executive Officer
Date and Time: May 24, 2016: 08.00 AM EDT
Webcast: A webcast of the presentation will be available through the details listed below
- Jefferies 2016 Healthcare Conference
Venue: Grand Hyatt New York Hotel, New York City
Presenter: Matt Kapusta, Chief Financial Officer
Date and Time: June 10, 2016: 11.00 AM EDT
The webcast, including a slide presentation at the 2016 UBS Global Healthcare Conference, can be accessed through the following link: https://cc.talkpoint.com/ubsx001/052316a_ae/?entity=47_SI2EH82 or by accessing the link displayed in the "Events" section on the "Media" page of the uniQure website at: http://www.uniqure.com/news/calendar-of-events/. The replay of the webcast will be available one hour after the conclusion of the live event and archived on the uniQure website for at least 30 days following the webcast.
About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with CNS, liver/metabolic and cardiovascular diseases. www.uniQure.com
CONTACT: uniQure:
Eva Mulder
Direct : +31 20 240 6103
Main: +31 20 240 6000
[email protected]
Media inquiries:
Gretchen Schweitzer or Stephanie May
MacDougall Biomedical Communications
Direct: +49 172 861 8540 or +49 175 5711562
Main: +49 89 2424 3494 or +1 781 235 3060
[email protected]


TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Italy Fines Apple €98.6 Million Over App Store Dominance
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 



